Sana Biotechnology has patented engineered cells with reduced MHC expression and increased CD47 expression, including hypoimmunogenic CAR-T cells. The cells also express chimeric antigen receptors with specific amino acid sequences. This innovation aims to enhance cell therapy efficacy and reduce immune rejection. GlobalData’s report on Sana Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sana Biotechnology, Viral vectors was a key innovation area identified from patents.
Engineered t cell with reduced mhc expression and car
A recently granted patent (Publication Number: US11987628B2) discloses an engineered T cell designed for enhanced therapeutic potential. The engineered T cell is derived from a primary T cell and features reduced expression of B2M, CIITA, and/or T cell receptor (TCR)-alpha compared to control T cells. Additionally, the engineered T cell expresses CD47 from a first exogenous polynucleotide, leading to increased CD47 levels, and a CD22-specific chimeric antigen receptor (CAR) from a second exogenous polynucleotide. The CAR includes specific antigen binding domains, hinge domains, transmembrane domains, costimulatory domains, and intracellular signaling domains, providing a comprehensive approach to targeted therapy.
Furthermore, the patent details the insertion of exogenous polynucleotides encoding CD47 and the CAR into the engineered T cell at specific loci, enhancing the precision and efficacy of the engineered T cell. The engineered T cell also exhibits reduced surface expression of human leukocyte antigen (HLA) class I antigens, HLA class II antigens, and/or TCR-alpha, potentially minimizing immune rejection responses. The pharmaceutical composition comprising the engineered T cell and a carrier offers a promising therapeutic option for various conditions. The use of viral transduction, particularly lentivirus-based vectors, ensures efficient delivery of the exogenous polynucleotides, further highlighting the innovative approach outlined in the patent. Overall, the patent showcases a novel engineered T cell design with potential applications in targeted immunotherapy and personalized medicine.
To know more about GlobalData’s detailed insights on Sana Biotechnology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
